Rain Oncology Inc.

NasdaqGS:RAIN Stock Report

Market Cap: US$44.0m

Rain Oncology Valuation

Is RAIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RAIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RAIN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RAIN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RAIN?

Key metric: As RAIN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RAIN. This is calculated by dividing RAIN's market cap by their current book value.
What is RAIN's PB Ratio?
PB Ratio0.7x
BookUS$67.52m
Market CapUS$44.03m

Price to Book Ratio vs Peers

How does RAIN's PB Ratio compare to its peers?

The above table shows the PB ratio for RAIN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.6x
SCYX SCYNEXIS
0.9x48.7%US$52.0m
VYNE VYNE Therapeutics
0.7x-18.2%US$43.7m
CALC CalciMedica
5.2x-9.4%US$46.5m
ETST Earth Science Tech
11.8xn/aUS$45.4m
RAIN Rain Oncology
0.7x23.3%US$44.0m

Price-To-Book vs Peers: RAIN is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (1.3x).

Price to Book Ratio vs Industry

How does RAIN's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

24 CompaniesPrice / BookEstimated GrowthMarket Cap
CTXR Citius Pharmaceuticals
0.3x55.3%US$25.65m
SHWZ Medicine Man Technologies
0.09xn/aUS$8.02m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.11m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.81m
RAIN 0.7xIndustry Avg. 1.8xNo. of Companies28PB01.22.43.64.86+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: RAIN is good value based on its Price-To-Book Ratio (0.7x) compared to the US Pharmaceuticals industry average (1.4x).

Price to Book Ratio vs Fair Ratio

What is RAIN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RAIN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RAIN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RAIN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
Nov ’25n/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
Oct ’25n/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
Sep ’25n/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
Aug ’25n/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
Jul ’25n/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
Jun ’25n/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
May ’25n/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
Apr ’25n/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
Mar ’25n/a
US$1.30
0%
24.7%US$1.75US$1.00n/a3
Feb ’25US$1.21
US$1.30
+7.7%
24.7%US$1.75US$1.00n/a3
Jan ’25US$1.20
US$1.30
+8.6%
24.7%US$1.75US$1.00n/a3
Dec ’24US$1.11
US$1.44
+29.5%
31.0%US$2.00US$1.00n/a4
Nov ’24US$1.08
US$4.55
+321.3%
137.1%US$17.00US$1.00n/a5
Oct ’24US$0.86
US$4.55
+428.0%
137.1%US$17.00US$1.00n/a5
Sep ’24US$1.03
US$4.65
+351.5%
133.0%US$17.00US$1.00n/a5
Aug ’24US$1.27
US$3.78
+197.5%
143.2%US$17.00US$1.00n/a7
Jul ’24US$1.20
US$3.78
+214.9%
143.2%US$17.00US$1.00n/a7
Jun ’24US$1.11
US$6.06
+446.3%
114.1%US$17.00US$1.20n/a7
May ’24US$7.34
US$18.00
+145.2%
21.5%US$24.00US$11.00n/a10
Apr ’24US$8.74
US$18.00
+105.9%
21.5%US$24.00US$11.00n/a10
Mar ’24US$9.49
US$18.67
+96.7%
26.2%US$29.00US$12.00n/a9
Feb ’24US$9.26
US$18.67
+101.6%
26.2%US$29.00US$12.00US$1.219
Jan ’24US$8.00
US$18.17
+127.1%
34.6%US$29.00US$12.00US$1.206
Dec ’23US$7.98
US$18.17
+127.7%
34.6%US$29.00US$12.00US$1.116
Nov ’23US$6.05
US$18.00
+197.5%
38.5%US$30.00US$10.00US$1.086

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.23

7D

0.6%

1Y

13.2%

Collegium Pharmaceutical

US$983.6m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.50

7D

1.8%

1Y

19.1%

Teva Pharmaceutical Industries

US$19.0b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.78

7D

-2.0%

1Y

72.8%